NOT-HL-23-076: Notice to Clarify the Research Strategy Page Limitations in RFA-HL-24-001 "Pediatric Heart Network Clinical Research Centers (UM1 Clinical Trial Optional)"

Notice to Clarify the Research Strategy Page Limitations in RFA-HL-24-001 "Pediatric Heart Network Clinical Research Centers (UM1 Clinical Trial Optional)"

Notice Number:

NOT-HL-23-076

Key Dates

Release Date:

February 17, 2023

Related Announcements

RFA-HL-24-001 - Pediatric Heart Network Clinical Research Centers (UM1 Clinical Trial Optional)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to clarify the page limitations for the Research Strategy subsections of RFA-HL-24-001 "Pediatric Heart Network Clinical Research Centers (UM1 Clinical Trial Optional)".

Currently reads:

Section IV. Application and Submission Information

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.

Modified to read (changes shown in bold italics):

Section IV. Application and Submission Information

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.

The Research Strategy section must not exceed 12 pages.

All other aspects of RFA-HL-24-001 remain unchanged.

Inquiries

Please direct all inquiries regarding this Notice to:

Scientific/Research Contact(s)

D'Andrea Egerson, RN, MSN
National Heart, Blood, and Lung Institute (NHLBI)
Telephone: 301-443-7045
Email: [email protected]

Gail Pearson, MD, ScD
National Heart, Blood, and Lung Institute (NHLBI)
Telephone: 301-435-0477
Email: [email protected]